Trials / Completed
CompletedNCT02014363
Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)
Double Blind, Non-inferiority Study to Evaluate the Antidepressant Activity of ETS6103 Compared to Amitriptyline in Treating Major Depressive Disorder in Patients With Unsatisfactory Response to Selective Serotonin Re-uptake Inhibitors.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 164 (actual)
- Sponsor
- e-Therapeutics PLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate that the antidepressant activity of ETS6103 is not inferior to amitriptyline in subjects who have an unsatisfactory response to / are resistant to treatment with SSRIs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ETS6103 (low dose) | |
| DRUG | ETS6103 (high dose) | |
| DRUG | Amitriptyline |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2015-10-01
- Completion
- 2015-10-01
- First posted
- 2013-12-18
- Last updated
- 2017-01-11
- Results posted
- 2017-01-11
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02014363. Inclusion in this directory is not an endorsement.